Bio Pharma Dive
SEPTEMBER 16, 2022
The public-private partnership plans to bring together scientific experts, private entities and patient groups to better understand certain neurodegenerative disorders and find new treatments.
Pharmaceutical Technology
SEPTEMBER 13, 2022
Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft's computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 16, 2022
The Indian Patent Office (IPO) has refused the patent application of Japanese drug maker Mitsubishi Tanabe Pharma Corporation for exclusive rights for its innovation related to type 2 diabetes drug teneligliptin, in favour of a pre-grant opposition filed by Mumbai-based pharma major Glenmark Pharmaceuticals Ltd. The company filed the patent application on July 11, 2012 […].
World of DTC Marketing
SEPTEMBER 12, 2022
Apple’s Health app gets new capabilities with iOS 16. The Health app adds Medications, allowing users to conveniently build and manage a medications list, create schedules and reminders, and track their medications, vitamins, or supplements. Will it matter? The health app will also tell users about potential interactions between medications, and it’s possible to connect with healthcare providers to see a list of past medications, get future updates, or add items to your schedule.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
SEPTEMBER 16, 2022
The startup’s $185 million initial public offering is the largest for the sector since early May and potentially a sign of renewed investor interest in young biotechs.
Pharmaceutical Technology
SEPTEMBER 16, 2022
Gilead Sciences has received expanded recommendation under the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline for the use of Veklury (remdesivir) to treat severe Covid-19 patients. The guideline update comes after the treatment received recommendation from the health agency for treating non-severe Covid-19 in patients at increased risk of hospitalisation.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
SEPTEMBER 12, 2022
Collaboration will involve sophisticated screening for cardiac-based drug discovery
Bio Pharma Dive
SEPTEMBER 16, 2022
The drug, meant to complement other treatments for paroxysmal nocturnal hemoglobinuria, comes via Alexion, which had acquired it from Achillion in 2019.
Pharmaceutical Technology
SEPTEMBER 15, 2022
Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 14, 2022
The medical devices industry in the country has sought the Centre to define online and offline mode of sale, provide more clarity on the regulations that are binding the online sales and suggested inclusion of online medical devices players under the Uniform Code for Medical Devices Marketing Practices (UCMDMP). The Association of Indian Medical Device […].
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
SEPTEMBER 16, 2022
Therapy has been developed for the prevention of disease in infants
Bio Pharma Dive
SEPTEMBER 16, 2022
A gene discovery four years ago led to a partnership between the companies, which plan to start a Phase 2 study later this year after encouraging early data.
Pharmaceutical Technology
SEPTEMBER 12, 2022
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb ’s (BMS) Sotyktu (deucravacitinib) to treat adult patients with moderate-to-severe plaque psoriasis. The oral treatment is indicated for such patients who are candidates for systemic therapy or phototherapy. It should not be used along with other immunosuppressants.
NPR Health - Shots
SEPTEMBER 16, 2022
They argue the threat posed by COVID has lessened because of preexisting immunity and access to treatment. Plus, some deaths may be incorrectly blamed on COVID. Others caution it's too soon to tell.
Pharma Times
SEPTEMBER 13, 2022
Up-LIFT research achieves primary endpoint with improvement in arm and hand function
Bio Pharma Dive
SEPTEMBER 16, 2022
Preliminary study results show the biotech’s gene editing treatment could reduce markers and symptoms of hereditary angioedema, though the data come from few patients and follow-up remains limited.
Pharmaceutical Technology
SEPTEMBER 14, 2022
Tumour-infiltrating lymphocyte (TIL) therapy has been investigated as a treatment modality for melanoma for almost 20 years. As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. Before TIL infusion, the patient undergoes lymphodepletion, which reduces the proportion of myeloid immune suppressive cells and creates space for the incoming lymphocytes.
STAT News
SEPTEMBER 10, 2022
Earlier this year, a leading animal rights group asked U.S. authorities to investigate medical research labs for allegedly violating federal law after finding numerous instances where nearly 2,000 monkeys were shipped between facilities without required veterinary inspections. Now, the federal government appears to be acting.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
SEPTEMBER 13, 2022
Modelling indicates a 307% increase in cases identified between 2020 and 2021
Bio Pharma Dive
SEPTEMBER 10, 2022
Sotyktu has been on the pharma’s top pipeline candidates and its clearance continues a string of positive regulatory news for the company.
Pharmaceutical Technology
SEPTEMBER 13, 2022
The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. With success in the metastatic setting, pharma companies, researchers and physicians have invested heavily in exploring the use of immune checkpoint inhibitors (ICIs) for the treatment of locally advanced disease, hoping to increase response rates and prevent disease progression.
NPR Health - Shots
SEPTEMBER 14, 2022
The ACA has required health insurers to provide many medical screenings and other preventive services with no out-of-pocket cost to health plan members. But a recent court decision could upend that.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
STAT News
SEPTEMBER 15, 2022
Artificial intelligence is a transformative tool in the workplace — except when it isn’t. For top managers, state-of-the art AI tools are a no-brainer: in theory, they increase revenues, decrease costs, and improve the quality of products and services. But in the wild, it’s often just the opposite for frontline employees who actually need to integrate these tools into their daily work.
Bio Pharma Dive
SEPTEMBER 14, 2022
The well-funded startup is planning Phase 3 trials for a drug it claims could be superior to top-selling medicines from Novartis and others.
Pharmaceutical Technology
SEPTEMBER 13, 2022
Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Although many patients are diagnosed with early-stage disease, almost a third progress to metastatic disease, with a five-year survival rate of just 30%.
NPR Health - Shots
SEPTEMBER 12, 2022
A new study suggests that. yes, there are superdodgers. But explaining why they've been able to avoid the virus is a bit complicated.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT News
SEPTEMBER 13, 2022
Akero Therapeutics said Tuesday that an experimental medicine improved liver scarring at twice the rate of a placebo without worsening other symptoms — achieving the main goal of a mid-stage clinical trial involving patients with the fatty liver disease known as NASH. If the encouraging study results are confirmed in later Phase 3 clinical trials, the Akero drug, called efruxifermin, could become an effective treatment for a chronic disease that has grown into one of the leading causes of
Bio Pharma Dive
SEPTEMBER 14, 2022
The trial, expected to enroll 25,000 adults, is the second late-stage test of an mRNA flu shot to begin this year, following the June start of a Moderna study.
Pharmaceutical Technology
SEPTEMBER 14, 2022
This week, at the European Society of Medical Oncology (ESMO) Congress 2022 researchers presented encouraging updates on immunotherapies in the field of cervical cancer. Positive data with checkpoint inhibitor combinations in particular garnered attention for their potential in broader patient groups. September marks Gynaecological Cancer awareness month, and cervical cancer ranks as the fourth most prevalent cancer for women worldwide.
Pharma Times
SEPTEMBER 12, 2022
Tislelizumab shows favourable safety profile compared to sorafenib among liver cancer patients
Expert insights. Personalized for you.
354 
Let's personalize your content